Literature DB >> 28244558

Assessing the Appropriateness of Oral Anticoagulation for Atrial Fibrillation in Advanced Frailty: Use of Stroke and Bleeding Risk-Prediction Models.

R O'Caoimh1, E Igras, A Ramesh, B Power, K O'Connor, R Liston.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is common among frail older adults. Oral anticoagulation (OAC) is particularly challenging for these due to overlapping stroke and bleeding risk factor profiles.
OBJECTIVE: To compare the utility of stroke and haemorrhage risk-prediction instruments in the treatment of AF among frail older adults.
DESIGN: Cross-sectional study. SETTINGS AND PARTICIPANTS: Frail residents in four nursing homes with a Clinical Frailty Scale score ≥5 (median 7±0). MEASUREMENTS: The prevalence of AF was assessed by ECG and chart review. Stroke (CHADS2 and CHA2DS2-VASc) and bleeding (HASBLED and HEMORR2HAGES) risk-prediction scores were then applied. A validated, risk-based, colour-coded decision support tool, incorporating these instruments, was then used to create a risk matrix and assess the appropriateness of OAC.
RESULTS: In total, 225 patients were included. The distribution of CFS scores was similar irrespective of AF status. In all, 86/225 (38%) had any history of AF. Of these, only 15/86 (17%) were prescribed OAC. All those in AF scored ≥2 on the CHA2DS2-VASc. One-third also scored high-risk of bleeding using HAS-BLED or HEMORR2HAGES. Risk-prediction scores were similar between those with 'known' (documented) and occult (only on ECG) AF. The colour-coded decision tree suggested that OAC would be recommended for the majority in AF when HAS-BLED (60/86, 70%) was used as the bleeding risk-prediction instrument. Despite this, only 12/60 (20%) were anticoagulated. When HEMORR2HAGES was incorporated instead, one patient was advised OAC, the remainder no treatment (57%) or an antiplatelet (42%). DISCUSSION: Stroke risk was high and bleeding risk levels comparatively low, suggesting that the balance of risk may favor OAC for AF in this cohort of patients with advanced frailty. Despite this and the high prevalence of AF, OAC prescription rates were low. The decision-support tool used showed mixed results, depending on the bleeding-risk score incorporated, suggesting that while useful, they should not replace clinical judgement.

Entities:  

Keywords:  Frailty; atrial fibrillation; haemorrhage; long-term care; prevalence; risk prediction instruments; stroke

Mesh:

Substances:

Year:  2017        PMID: 28244558     DOI: 10.14283/jfa.2016.118

Source DB:  PubMed          Journal:  J Frailty Aging        ISSN: 2260-1341


  5 in total

1.  Prevalence of Frailty and Associations with Oral Anticoagulant Prescribing in Atrial Fibrillation.

Authors:  Saket R Sanghai; Weisong Liu; Weijia Wang; Subendhu Rongali; Ariela R Orkaby; Jane S Saczynski; Adam J Rose; Alok Kapoor; Wenjun Li; Hong Yu; David D McManus
Journal:  J Gen Intern Med       Date:  2021-05-04       Impact factor: 5.128

2.  Hospitalized frail elderly patients - atrial fibrillation, anticoagulation and 12 months' outcomes.

Authors:  Niklas Ekerstad; Thomas Karlsson; Sara Söderqvist; Björn W Karlson
Journal:  Clin Interv Aging       Date:  2018-04-26       Impact factor: 4.458

3.  Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment.

Authors:  Jose María Mostaza; Manuel Jesús Romero Jiménez; Fernando José Ruiz Laiglesia; José Antonio Díaz Peromingo; Manuel Beltrán Robles; Ernesto Guevara Sierra; Ana Santander Bilbao; Carmen Suárez
Journal:  J Geriatr Cardiol       Date:  2018-04       Impact factor: 3.327

4.  Anticoagulant Therapy for Frail Patients with Atrial Fibrillation.

Authors:  Hiroshi Hori; Takahiko Fukuchi; Hitoshi Sugawara
Journal:  Intern Med       Date:  2021-02-15       Impact factor: 1.271

5.  Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis.

Authors:  Chris Wilkinson; Oliver Todd; Andrew Clegg; Chris P Gale; Marlous Hall
Journal:  Age Ageing       Date:  2019-03-01       Impact factor: 10.668

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.